Search for: "ALTERNATIVE BRANDS, INC. " Results 581 - 600 of 908
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
11 Sep 2012, 1:36 am by Kevin LaCroix
The TJX Companies also fell victim to a cyber intrusion that security experts predict will have long-term costs of between US$4 billion and US$8 billion in fines, legal fees, notification expenses and brand impairment. [read post]
31 Aug 2012, 2:10 am by John L. Welch
Doctor's Associates, Inc., Opposition No. 91192657 [Opposition to registration of FOOTLONG for "sandwiches" on the grounds of genericness or, alternatively, mere descriptiveness and lack of secondary meaning].Text Copyright John L. [read post]
31 Jul 2012, 7:25 am by aschwartz
 The FTC report concluded that as a result of such agreements, “brand-name pharmaceutical prices stay high, and the brand and generic share the benefits of the brand’s monopoly profits. [read post]
20 Jul 2012, 11:45 am by Bexis
  The claims (allegations of failure to warn that the generic version of a drug supposedly wasn’t really as safe or effective as the original branded version) were flat out preempted by PLIVA, Inc. [read post]
19 Jun 2012, 7:08 am by Rebecca Tushnet
Warner Brothers Entertainment Inc., 11 Civ. 9436 (ALC) (HBP) (S.D.N.Y. [read post]
1 Jun 2012, 5:06 am by Jim Singer
There is more than one way to seal a bottle with wax to make it look appealing, and so Cuervo fails the comparable alternatives test. [read post]
30 May 2012, 8:28 am by Michelle Yeary
Teva Pharmaceuticals USA, Inc., 2012 U.S. [read post]
7 May 2012, 5:00 am by Bexis
Body Masters Sports Industries, Inc., 784 A.2d 1178, 1183 (N.H.2001), the New Hampshire Supreme Court rejected the Third Restatement because of the alternative design issue. [read post]
4 May 2012, 12:19 pm by Rebecca Tushnet
N2G Distributing, Inc., 2012 WL 1402818 (E.D. [read post]
1 May 2012, 6:49 pm by Dan Bushell
Watson Pharmaceuticals, Inc., (a/k/a In re: Androgel Antitrust Litigation) addressing the prominent antitrust/patent/health care law issue of the validity of so-called "reverse payment" or "pay for delay" settlements between pharmaceutical patent holders (i.e. name brand drug makers) and competing drug makers seeking to market generic alternatives. [read post]